ImmuCell Corp. said Friday it received a two-year, $446,000 Phase IISmall Business Innovation Research (SBIR) grant from the NationalInstitute of Allergy and Infectious Diseases.The grant will be used to develop recombinant vaccines toCryptosporidium parvum, which causes severe, chronic diarrhea inimmunocompromised people. The vaccines will be developed incollaboration with Carolyn Petersen at the University of California atSan Francisco.ImmuCell also said it obtained an exclusive worldwide license from theUniversity of California on several cloned antigens of Cryptosporidiumparvum, for which a patent has been applied._Jim Shrine

(c) 1997 American Health Consultants. All rights reserved.